Literature DB >> 21570966

Experimental infection with Rangelia vitalii in dogs: acute phase, parasitemia, biological cycle, clinical-pathological aspects and treatment.

Aleksandro S Da Silva1, Raqueli T França, Marcio M Costa, Carlos B Paim, Francine C Paim, Guilherme L Dornelles, João F Soares, Marcelo B Labruna, Cinthia M Mazzanti, Silvia G Monteiro, Sonia T A Lopes.   

Abstract

Recently we conducted the molecular characterization of Rangelia vitalii, a protozoan with high pathogenicity for young dogs in southern Brazil. To date, the descriptions of the disease have been restricted to natural infection cases. Therefore, this study aimed to evaluate the parasitemia, biological cycles and clinical-pathological findings in dogs experimentally infected with R. vitalii in the acute phase of disease, and also aimed to test a therapeutic protocol based on the diminazene aceturate. For this study, we used 12 young dogs (females), separated into two groups. Group A was composed of healthy dogs, not-infected (n=5), and Group B consisted of animals infected with R. vitalii (n=7). After infection, the animals were monitored by blood smear examinations, which showed intra-erythrocytic forms of the parasite 5 days post-infection (PI). Parasitemia increased progressively in these animals and had the highest peak of circulating parasites between 9 and 11 days PI. Subsequently, the parasitemia reduced and the protozoan was seen inside the leukocytes in days 17, 19 and 21 PI. The most prominent clinical signs observed at the 20 day PI of experiment were lethargy, fever and anorexia. We observed a decrease of hematocrit of infected animals compared with not-infected dogs, featuring a moderate anemia. Pathological evaluation of one dog in Group B at day 21 PI revealed splenomegaly, hepatomegaly, lymphadenopathy, and hemorrhages at necropsy. Histological examination showed only follicular hyperplasia in the spleen and lymph nodes, and the etiologic agent in the vascular endothelium. At 21 days PI, it was performed the treatment of dogs in Group B (n=6) with a single dose of diminazene aceturate, which showed a curative efficacy of 100% in cleaning R. vitalii from blood of infected dogs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570966     DOI: 10.1016/j.exppara.2011.04.010

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  4 in total

1.  Canine rangeliosis: the need for differential diagnosis.

Authors:  Aleksandro Schafer Da Silva; Danieli Brolo Martins; João Fabio Soares; Raqueli Teresinha França
Journal:  Parasitol Res       Date:  2012-10-09       Impact factor: 2.289

2.  Rangelia vitalii in a free-ranging maned wolf (Chrysocyon brachyurus) and co-infections.

Authors:  Julia Angélica Gonçalves Silveira; Mirella Lauria D'Elia; Isabela de Oliveira Avelar; Lara Ribeiro de Almeida; Hudson Andrade Dos Santos; Danielle Ferreira de Magalhães Soares; Múcio Flávio Barbosa Ribeiro; Walter Dos Santos Lima; Roselene Ecco
Journal:  Int J Parasitol Parasites Wildl       Date:  2016-09-22       Impact factor: 2.674

3.  Microscopic Detection, Hematological Evaluation and Molecular Characterization of Piroplasms from Naturally Infected Dogs in Rio de Janeiro, Brazil.

Authors:  Fernanda Barbosa Dos Santos; Gilberto Salles Gazêta; Laís Lisboa Corrêa; Lucas Fernandes Lobão; João Pedro Siqueira Palmer; Laís Verdan Dib; José André Lessa Damasceno; Nicole Oliveira Moura-Martiniano; Otilio Machado Pereira Bastos; Claudia Maria Antunes Uchôa; Alynne da Silva Barbosa
Journal:  Acta Parasitol       Date:  2021-06-15       Impact factor: 1.440

4.  Increased cytokine and nitric oxide levels in serum of dogs experimentally infected with Rangelia vitalii.

Authors:  Francine C Paim; Aleksandro S Da Silva; Carlos Breno V Paim; Raqueli T França; Márcio M Costa; Marta M M F Duarte; Manuela B Sangoi; Rafael N Moresco; Silvia G Monteiro; Sonia Terezinha A Lopes
Journal:  Korean J Parasitol       Date:  2013-02-18       Impact factor: 1.341

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.